SBC Medical Group Holdings Inc., a Japanese owner and operator of aesthetic medical clinics, has officially entered the U.S. market through a strategic investment in OrangeTwist, a U.S.-based medspa chain. This move represents the initial phase of SBC's comprehensive plan to expand internationally, with a focus on the U.S. and Southeast Asia. The company, which already manages a global network of 258 affiliated clinics and over six million patient visits annually, views this partnership as the start of its full-scale strategic expansion in the United States.
OrangeTwist operates 24 locations across six U.S. states, specializing in non-invasive aesthetic treatments including injectables, energy-based procedures, and regenerative therapies. SBC cited OrangeTwist's advanced management system, which integrates procurement, clinical workflows, and real-time KPI tracking, as providing operational consistency that supports scalable growth. According to Yoshiyuki Aikawa, CEO of SBC Medical Group Holdings, OrangeTwist has established leadership in the U.S. market through consistent delivery of exceptional quality and outstanding client experiences in non-invasive aesthetic medicine.
The partnership will enable both companies to pursue joint operations while leveraging synergies between the U.S. and Asian markets. Beyond selling each other's services and products in their respective regions, the companies plan to collaborate on developing new beauty products and services. Robert Settembro, CEO of OrangeTwist, expressed enthusiasm about deepening the strategic partnership while expanding presence in high-growth markets, emphasizing continued focus on high-quality care, best-in-class providers, and innovative services that differentiate OrangeTwist in the rapidly growing aesthetic landscape.
The U.S. market represents a significant opportunity for SBC Medical Group, with the medical aesthetics industry projected to grow from $34 billion to $48 billion by 2030 according to company reports. Drivers of this growth include increasing demand for non-surgical treatments such as injectables, fillers, laser treatments, and body contouring procedures that offer minimal risk and downtime. The aging U.S. population is also contributing to rising demand for aesthetic treatments.
This investment represents the first step in SBC's multi-year roadmap to establish leading positions in medical aesthetics and wellness markets. During 2026, the company plans additional strategic investments and partnerships similar to the OrangeTwist arrangement. SBC has already expanded in Southeast Asia through an e-consulting agreement with BLEZ ASIA Co. Ltd., which operates more than 20 pharmacies and clinics in Thailand. As part of that partnership, SBC will provide management support for a new dermatological clinic BLEZ is preparing to open in Bangkok, focusing on treatments for pigmentation and spot removal.
The company's expansion strategy unfolds across three distinct phases. Phase 1, currently underway, involves strategic investments and partnerships like those with OrangeTwist and BLEZ ASIA. Phase 2, scheduled for 2027 and 2028, will focus on select acquisitions and joint ventures to accelerate growth and enhance competitive positioning. Phase 3, beginning in 2029, represents when SBC expects to achieve leadership positions in the U.S., Southeast Asia, and other key markets. This structured approach demonstrates the company's methodical planning for international growth in the rapidly expanding medical aesthetics industry.
